Cogstate Limited
ASX:
CGS
Cogstate Ltd. is a global cognitive science company, which engages in delivering software services to optimize the measurement of cognition in clinical trials, academic research, healthcare and brain injury. It operates through the following segments: Clinical Trials, Healthcare, and Administration. The Clinical Trials segment provides solutions to optimize clinical outcome assessments to better measure drug efficacy and safety. The Healthcare segment offers tools to detect patient cognitive impairment and change throughout the continuum of care. Cogstate was founded by David Gordon Darby and Paul Maruff on December 17, 1999, and is headquartered in Melbourne, Australia.
Stock Performance Profile:
(Source: TradingView) One-Year Performance Profile of CGS compared to ASX 200 (XJO).
From the company reports:
FY24 Highlights:
Cogstate Limited (ASX: CGS) has recently published its financial results for the fiscal year 2024, concluding on June 30, 2024.
The company reported a Group Revenue of $43.4 million, reflecting a 7% increase compared to the previous corresponding period (PCP).
The Group’s Profit before Tax reached $7.1 million, marking a significant rise of 135% from the PCP.
In terms of Clinical Trials New Contract Sales, the figure stood at $27.0 million, which represents a decline of 21% from the PCP of $34.0 million; however, this figure encompasses critical milestones that are expected to drive future growth.
The contracted future revenue was reported at $110.9 million, down 16%.
Regarding cash flow and the balance sheet, the company achieved a positive cash flow from operations amounting to $5.8 million during FY24, a notable increase from $0.7 million in the PCP. As of June 30, 2024, the net cash balance was recorded at $29.4 million.
5-Year Financial Snapshot:
(Data Source: TradingView. Graphic Source: Pristine Gaze)
The company has successfully executed a significant operational transformation and experienced substantial financial growth over the last five years. Revenue increased from $33.9 million in 2020 to $66 million in 2024. Additionally, the company reversed its previous losses, moving from a deficit of $2.92 million in 2020 to achieving a profit of $7 million in 2021. This profitability continued to rise, reaching $8.32 million in 2024, with a peak exceeding $10 million in 2020.
Growth Catalyst:
(Graphic Source: Company Reports)
Cogstate is strategically positioned to take advantage of a considerable market opportunity within clinical trials, especially given its emphasis on the Central Nervous System (CNS). This area represents the second largest segment of the clinical trial market, holding an 18% share. With a substantial market size of $25 billion, the company is ideally situated to capitalize on this favorable opportunity for future growth, while also witnessing significant revenue growth from the same at present. Furthermore, the escalating prevalence of Alzheimer’s disease in the CNS segment globally is prompting considerable investments in research and development focused on this ailment. Simultaneously, the company’s dedication to diversifying its operations is particularly significant, especially through its brain assessment medical devices, which have received FDA approval for use by physicians. Having also regained its rights to this technology, the company is now positioned to earn substantial royalties from its sales, thereby offering a notable avenue for organizational growth.
Outlook:
(Graphic Source: Company Reports)
The company’s prospects for both the short and long term appear favorable, as evidenced by a robust beginning to FY25, marked by the acquisition of substantial sales contracts totaling nearly $40 million. Additionally, the company maintains a solid backlog, particularly in clinical trials, which amounts to $95 million. This backlog is anticipated to serve as a reliable source of revenue for the company over the long term, with realization expected to occur between FY25 and FY29 and extending beyond that period.
Risk Analysis:
The company is significantly vulnerable to substantial regulatory risks, as its profitability and operational stability are largely dependent on obtaining regulatory approvals and adhering to compliance requirements. Additionally, the threats associated with data theft and protection are also significant, necessitating ongoing proactive measures from the company to mitigate these risks.
Technical Analysis:
(Graphic Source: TradingView) CogstateLimited (ASX: CGS) Weekly Time-Frame (WTF) Chart.
Cogstate is currently engaged in testing its short-term 14-Day Exponential Moving Average (EMA), with a potential breakthrough signaling the initiation of a favorable trend reversal in the near term. Concurrently, the security is experiencing a rebound from its lower Bollinger Bands, which further suggests the possibility of a trend reversal. Additionally, the increasing Relative Strength Index (RSI) reflects a positive shift in market sentiment regarding the security, with the 14-Day RSI at 44 indicating the potential for significant upward movement.
Analyst’s Take:
Cogstate, despite its current trading levels being significantly lower than those observed a few years ago, continues to exhibit remarkable revenue and earnings growth over the long term. This sustained performance has led to a notable decrease in the company’s valuations, as evidenced by a reduction in the price-to-earnings (P/E) ratio from an average exceeding 30x in recent years to approximately 20x at present. This decline presents a substantial discount for investors, even in light of the company’s impressive fundamental and operational advancements, as well as its promising short-term and long-term financial growth prospects. Furthermore, the company’s initiatives regarding share buybacks are likely to enhance shareholder value, resulting in an increase in individual monetary output for shareholders.
As per Pristine Gaze, you may consider a “Buy” on “Cogstate Limited” at the closing price of “$0.995” (As of 18 November 2024).
*All currency figures are in Australian Dollars unless stated otherwise.
*All data sourced from Company Reports and TradingView.
Disclaimer
The reports provided by Pristine Gaze are designed to deliver comprehensive stock and sector analysis, market insights, and investment recommendations, drawing upon our research and expertise. However, it is important to note that these reports are intended for informational purposes only and do not constitute personalised financial advice. They do not consider your individual investment objectives, financial situation, or specific needs.
Before making any investment decisions based on the insights and recommendations included in these reports, we strongly advise consulting with a qualified financial advisor who can provide tailored advice that aligns with your personal circumstances.
Pristine Gaze, including its directors, employees, associates, and affiliates, assumes no liability for any loss or damage incurred as a result of relying on the information or recommendations provided in these reports. This encompasses, but is not limited to, direct, indirect, incidental, or consequential losses.
While we endeavour to ensure the accuracy and timeliness of the information presented in our reports, we cannot guarantee its completeness or accuracy, and the content may change without prior notice. The inclusion of any stock or sector within these reports does not serve as an endorsement or recommendation, and such mentions may be altered or removed at any time.
These reports may reference external data or links to third-party resources, for which Pristine Gaze takes no responsibility. The use of such information or resources is at your own risk.
All content within the Pristine Gaze reports, including but not limited to text, graphics, and analysis, is the intellectual property of Pristine Gaze and is protected under applicable copyright and trademark laws. Unauthorised use or distribution of this content without prior consent is prohibited.
By accessing or utilising Pristine Gaze’s reports, you acknowledge and agree to the terms outlined in this disclaimer. For further details, please refer to our full Terms and Conditions and Privacy Policy.
